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Cardiovascular imaging
An European Society of Cardiology/European Association of
Cardiovascular Imaging task force is examining the appropriate
use of cardiovascular imaging in Europe
Cardiovascular imaging (CVI) is evolving rapidly, placing new
demands on our profession for training, education, and advocacy. It
is likely that the need for CVI will continue to increase over the
coming years due to the changes in cardiovascular disease epidemi-
ology and ageing of the population. However, there are major in-
equalities in the access to CVI across Europe with important
restrictions in some European regions reported recently. Further-
more, reliable statistics on the current CVI practice in Europe are
lacking. Establishing the current status of the use of CVI in Europe
has thus become an urgent priority.
Recentevidence indicates that a considerablepercentageofmedical
imaging studies are unnecessary or inappropriate. The FDA estimates
that 30–50% of all medical imaging exams are not medically necessary.
Are these figures transferable to Europe? Intuitively, the explosive
growth in CVI use could be similar in all industrialized countries.
Currently, there is growing interest in the scientific community in
the appropriate use of CVI techniques for diagnosis and decision-
making in Europe. Determining the appropriateness of individual
medical imaging procedures is however challenging, since the rele-
vance of CVI may vary with patients’ characteristics, local facilities,
the degree of expertise of the imagers, and the rapid evolution of
the imaging technologies.
The EACVI leadership at the behest of its current president, Prof.
Patrizio Lancellotti, and with the help of Professors Gilbert Habib,
Sven Plein, and Danilo Neglia, has decided to create a dedicated
European Society of Cardiology/European Association of Cardiovas-
cular Imaging (ESC/EACVI) Taskforce on CVI whose mission is to
summarize and present the main issues pertaining to our knowledge
of the appropriate use of CVI in Europe.
The major goals of the Taskforceare (i) to carryout surveys onCVI
practice in Europe; (ii) to defineappropriateness criteria and describe
appropriate and inappropriate CVI use cases; (iii) to improve aware-
ness of the appropriate use of CVI in Europe; (iv) to provide health-
care providers with information about the utilization of CVI in
Europe; (v) to position ESC/EACVI as the referenced multi-modality
CVI body towards European institutions; (vi) to become a federating
body for exchange with other imaging specialists (in particular Radi-
ologists and Nuclear Imaging Specialists); (vii) to carry out prospect-
ive registries and outcome studies on imaging.
Action plan as follows:
(1) A mapping of the useofCVI techniques for diagnosis and decision-
making across Europe represents the first comprehensive project
of the ESC/EACVI Taskforce on CVI. Country-specific data will be
gathered through different sources, in particular the National
Societies. A ‘Cardiovascular Highlight book’ will contain data
from a survey of the current use of CVI in the ESC membership
countries. The project has been recently launched and 19 coun-
tries have already returned the required data.
(2) OwingtothegrowingdemandfordiagnosticCVI, thedevelopment
of criteria to aid appropriate use and planning of CVI availability
becomes essential. Developing and implementing appropriateness
criteria for CVI is thus another key objective of the Taskforce. By
establishing appropriateness criteria, the ESC/EACVI Taskforce
aims to safeguard the interest of the patients, of society as a
whole, and of the ESC/EACVI community while promoting homo-
geneous healthcare provision, and implementation of guidelines
and of evidence. Madalina Garbi, EACVI board member, has
played a key role in the finalization of the first document focusing
on the appropriateness criteria development process, which will
soon be published in the EHJ-CVI. Future Taskforce appropriate-
ness documents will focus on specific clinical conditions such as
heart failure or ischaemic heart disease.
(3) Although the value of imaging in the management of patients with
cardiovascular disease is indisputable, the impact of imaging on
clinical outcomes requires additional evidence. Therefore, the
ESC/EACVI Taskforce will also set up prospective outcome
studies, which aim (i) to strengthen the clinical value of CVI in
the diagnostic work-up; (ii) to define the respective value of
each imaging modality according to a specific clinical context;
(iii) to determine how CVI may affect clinical decision-making
and outcome. To reach these objectives, the ESC/EACVI Task-
force will use available data from large ESC registries or create
new prospective registries on specific clinical conditions (i.e.
heart failure, cardiac-oncology) or will implement newupcoming
ESC registries with targeted imaging questions. With the help of
the Committee for Research and Innovation of the EACVI,
European projects will be drawn up to raise the required funds.
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A case of translational research: calcium
transport in cardiomyocytes suggests novel
approaches to treating arrhythmias
Understanding electrophysiological events at the near-molecular
level is pointing to new ways of treating arrhythmias: physician–
scientist Prof. Karin Sipido, MD, PhD (Editor-in-Chief ofCardiovascular
Research) is working to translate her findings to the clinic, reports
Barry Shurlock PhD
One of the features of biomedical research over the last couple of
decades is that the science has become so complex that there is a
danger of clinicians and researchers running on parallel tracks that
never meet. The so-called ‘translation gap’ between scientific re-
search and clinical practice has, of course, received a lot of attention,
but, like the ‘toomuchpublished’ problem, therearenoeasyanswers.
In principle, the growing presence of the physician–scientist has done
much to bridge the gap, as clinical and bench research have become
more specialized, and fewer and fewer physicians are to be found in
basic research laboratories. Someone who is acutely aware of this is
Prof. Karin Sipido, MD, PhD, who is head of experimental cardiology
at the Catholic University of Leuven, Leuven, Belgium.
She said: ‘One of the points that I’m always bringing up in discussion
is that it’s very important to maintain exchanges and interactions
between clinically trained people and researchers, as there are now
very few scientists with clinical training that go into full-time research.
I go to the AHA and ESC meetings, as well as to the meetings of the
Biophysical Society and Physiological Society. But, we are few to do
so, a dying breed!’ Scientists with a PhD in life sciences and different
specialty training are well positioned to lead the experimental re-
search lab, while clinicians have the knowledge, expertise, and
access to patients to provide the translation, forward and reverse.
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Prof. Sipido manages to combine an active academic career with
involvement in a large number of bodies concerned with fostering re-
search, locally, nationally, and internationally. Last year, for example,
she became Editor-in-Chief of Cardiovascular Research and President
of the Alliance for Biomedical Research in Europe, which represents
21 medical societies and 400 000 researchers in the EU.
She has been a board member of the ESC (2004–06) and was co-
founder, and subsequently chairof the Council on Basic Cardiovascular
Sciences. She is also a member of the EU affairs committee responsible
for research and hasbeen a member of the Basic Science Council of the
AHA. Closer to home, she has chaired the Research Council of the
Catholic University of Leuven and was Research Coordinator for Bio-
medical Sciences. In the Flanders region of Belgium, she is a Board
member of the Center for Medical Innovation.
For people with such a strong administrative load, the laboratory
bench is often a distant memory, but not for Prof. Sipido. She con-
tinues to publish ground-breaking research, working with a group
of young enthusiastic postdoctoral and PhD students from all over
the world. Dr Sipido’s main field of interest is cardiac cellular electro-
physiology and calcium homoeostasis, especially the changes asso-
ciated with cardiac hypertrophy and heart failure. In collaboration
with other groups, she relates cellular data with in vivo findings. She
is particularly interested in the role of altered calcium homoeostasis
in cardiomyocytes, its role in arrhythmogenesis, and the potential for
targeting NCX (sodium calcium exchange) as therapy.Recognition of
her contributions has been marked by recent awards. In 2012 shewas
commended and accepted as member of the Academia Europaea,
and last year she received the Keith Reimer Award of the Internation-
al Society for Heart Research.
Much of her work is done with a fine ‘patch pipette’, only 2 mm in
diameter, which is placed on the surface of isolated cardiomyocytes
to record ion transport, while at the same time observing events
within the cell by means of a fluorescent indicator for cytoplasmic
calcium ion concentration and using confocal imaging. In this way, it
is possible to understand events in subcompartments and microdo-
mains of the cell, extending, with the latest techniques, down to the
levelof clusters of a fewmolecules. Importantly, thiswork showshow
calcium transport is altered in cardiomyocytes frompeoplewho have
suffered a myocardial infarction.
Beyond the sheer elegance of these techniques, Prof. Sipido is
confident that the findings contribute to identifying novel kinds of
antiarrhythmic therapy. She said: ‘We have shown that NCX is
closely involved in the generation of arrhythmias. Despite advances
in the use of implantable cardioverter-defibrillators, there is a
definite need for new drugs – a very different kind of drug from
classic drugs. NCX provides a new target for drug therapy, so that by
mild suppression of this kind of calcium transport, combined with
other targets, we believe it will be possible to improve the treatment
of arrhythmias’.
One of the reasons why Prof. Sipido and her colleagues are able
to carry out such sophisticated studies is that the Department of
Cardiovascular Sciences and the University Hospital in Leuven
provides an excellent research environment. The Department has
60 facultymembers,with awide rangeof expertise, includingmolecu-
lar biology, in vivo imaging, cell models, patient studies, and large
clinical trials. Importantly, the Division of Cardiac Surgery performs
20–25 heart transplants a year, and there is a dedicated,
round-the-clock, on-call team of scientists able to work on explanted
hearts. Additional work is done on small heart biopsies obtained
during valve surgery. She said: ‘There are very few studies of human
cardiomyocytes, which are difficult to obtain. The problem is that
the tissue samples are either very small or from very diseased
hearts and it’s therefore very difficult to isolate single working cells.
It doesn’t lend itself to the sort of protocols used in animal studies
with pigs and sheep. The department also has initiated several clinical
proof-of-concept studies, and this potential for translation, within
one department, creates a very attractive and powerful research
environment’.
GAP-AF study helps to define optimal approach
for atrial fibrillation ablation
Result of late breaking trial presented at European Heart Rhythm
Association EUROPACE 2013
Using catheter ablation to create complete linear lesions around
pulmonary veins proved more effective than the creation of
incomplete lesions in preventing recurrence of atrial fibrillation
(AF), reported the GAP-AF study. The study, presented in the
Late Breaking Clinical Trials session I at the EHRA EUROPACE
2013 meeting in Athens, Greece, represents the first time
that a randomized controlled study has been undertaken compar-
ing the two different ablation strategies for patients with paroxys-
mal AF.
Identification of triggers initiating AF within the pulmonary veins
led to prevention of AF recurrence by catheter ablation at the site
of origin of the trigger. The Heart Rhythm Society /European Heart
Rhythm Association/European Society of Cardiology Expert Con-
sensus Document on Catheter and Surgical Ablation of Atrial Fibril-
lation (published in 2007 and updated in 2012) states that patients
undergoing catheter ablation for AF should have complete isolation
of the pulmonary veins, which involves a complete circumferential
lesion being created around the pulmonary vein.
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‘This recommendationwas based onob-
servational studies, not on a prospective
randomized trial. But some electrophy-
siologists (EPs) continue to believe that
it’s sufficient to create incomplete linear
lesions where conduction sites still exist
between the pulmonary veins and left
atrium’, explained Prof. Karl Kuck, from Asklepios Klinik St George,
Hamburg, Germany, presenter of the GAP-AF study.
Part of their reasoning is that 95% of patients with AF recurrence
after complete pulmonary vein isolation (PVI) procedures are found
to have conduction gaps between the pulmonary veins and the left
atrium, he said. ‘Since they can’t isolate the pulmonary veins perman-
ently, they reason that incomplete isolation is sufficient and has the
advantage of being a shorter procedure with a potentially lower
complication rate and less cost’, said Prof. Kuck.
In theGAP-AF(AFNET1) studybetweenFebruary2006andAugust
2010, 233 patients with drug refractory paroxysmal AF were rando-
mized to have either a complete procedure (n ¼ 117) or an incom-
plete procedure (n ¼ 116). For the incomplete procedure, the EPs
stopped the radiofrequency application at one site to permit recon-
duction from the circumference. The study, which was performed in
seven German centres, was funded by the German Atrial Fibrillation
Network (AFNET). The inclusion criteria for the study were that
patients had to be aged over 55 years and to have been treated with
one antiarrhythmic drug before they entered the trial. Patients with
poor left ventricular function were excluded from the study.
The primary endpoint of the study was the time to first recurrence
of symptomatic AF with duration of.30 s on trans-telephonic ECG
monitoring, or detection of asymptomatic AF defined as two con-
secutive recordings of AF during a minimum of 72 h. The study
made use of the RhythmCard
TM
technology, a small credit card-sized
device that patients can place on their chest wall to record an ECG
whenever they experienced symptoms of AF and transmit the data
via the telephone. Additionally, patients were asked to record and
transmit an ECG every day regardless of their symptoms.
Results showed that at the 3-month follow-up, sinus rhythm had
been achieved in 37.8% (46) of patients who had complete ablation,
vs. 20.8% (26) with incomplete ablation (P, 0.001).
At 3 months, when patients were taken back to the EP lab for a
repeat investigation, 70% of those randomized to complete PVI had
gaps vs. 89% randomized to incomplete PVI.
No significant differences were found for serious adverse
events (including syncope, stroke, major bleeding, and tamponade)
between the complete and incomplete groups.
‘The study shows us for the first time that complete isolation of the
pulmonary veins is more effective than incomplete isolation. It sug-
gests that the level of evidence for complete ablation should be
upgraded from class Ic to class Ia, where it is supported by a multicen-
tre randomized trial’, said Prof. Kuck.
However, the study also highlighted that recurrence rates
were high even for patients who had undergone complete isolation
procedures. ‘Research is urgently needed to improve ablation tech-
niques to make the complete lines more durable. There is a need
to explore other energy sources and tools for catheter ablation’,
he said.
The fire and ice trial, for example, is currently underway to see
whether a thermoCool catheter might be more effective than cryoa-
blation for patients with paroxysmal AF.
Andros Tofield
Study of Ablation versus AntiaRrhythmic Drugs
in Persistent Atrial Fibrillation study shows
ablation superior to drugs for patients
with persistent atrial fibrillation
Results of late breaking trial presented at European Heart Rhythm
Association EUROPACE 2013
The Study of Ablation versus AntiaRrhythmic Drugs in Persist-
ent Atrial Fibrillation (SARA) study, presented in the Late
Breaking Clinical Trials session at EHRA EUROPACE 2013,
found that catheter ablation (CA) therapy was superior to
medical therapy for maintenance of sinus rhythm in patients
with persistent AF.
While a number of previous studies have shown the superiority
of CA over anti-arrhythmic drug therapy (ADT) for patients with
ThermoCoolw SF catheter Cryoablation catheter
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paroxysmal AF, no previous studies have been undertaken specifical-
ly comparing ablation to drugs in patients with persistent AF.
Principal investigator Prof. Lluis Mont, from the
Atrial Fibrillation Unit, University of Barcelona,
Spain explained, ‘Patients with persistent AF
have in general been considered bad candidates
for ablation due to poor results and the need for
prolonged and aggressive procedures’.
Between May 2009 and November 2011 in the
open parallel SARA study Prof. Mont and collea-
gues, from eight ablation centres in Spain, randomly assigned a total
of 146 patients with persistent AF 2 : 1 to CA (n ¼ 98) or ADT
(n ¼ 48). Antiarrhythmic drug therapy was given according to
current guidelines, with class III drugs (amiodarone) recommended
for patients with structural heart disease and class Ic (flecainide)
plus diltiazem or beta-blockers for patients without structural
heart disease. The inclusion criteria were: patients with persistent
atrial fibrillation of.7 days, or, 7 days that needed pharmacologic-
al or electrical cardioversion.
The study specifically excluded patients with chronic persistent
AF (continuous for .1 year) since this represents ‘a bad scenario
for ablation’ and also patients with extremely dilated atriums
(.50 mm antero-posterior diameters).
In an intention-to-treat analysis, the proportion of patients free of
prolonged (.12 h)AFat12months (primaryendpoint)was 70.4% in
the CA group vs. 43.7% in the ADT group (P ¼ 0.002); implying an
absolute risk difference of 26.6% (95% CI: 10.0–43.3) favouring the
ablation group.
The proportion of patients free of any recurrence of AF or atrial
flutter (lasting .30 s) was 60.2% in the CA group compared with
29.2% in the ADT group (P, 0.001).
‘The take home message is that AF ablation in persistent AF has
a reasonable success safety profile and can be offered to patients
resistant to ADT, provided some specific selection criteria are
applied, such as excluding patients with very dilated atrium and long-
standing persistent AF’, said Mont.
One weakness was that the study only recruited patients from ar-
rhythmia units. ‘Therefore they’re likely to represent a selected
population resistant to ADT’.
A challenge for increasing the number of ablation procedures
taking place was likely to be the shortage of highly trained physicians.
‘But as happened years ago with coronary angioplasty, the demand is
likely to increase the numbers of physicians and centres prepared to
perform such procedures’, said Prof. Mont.
Further studies, he added, are now needed, to look at outcomes
according to ‘shape remodelling’ and levels of fibrosis. ‘This should
help to further stratify patients and select good candidates for
ablation’, he concluded.
Andros Tofield
Catheter ablation of atrial fibrillation as first-line
treatment: is the future here now?
The prevalence of atrial fibrillation (AF) in Europe is increasing.1
Despite the benefits of maintaining sinus rhythm,2 pharmacological
strategies have not provided satisfactory results in randomized
studies, probably because their beneficial antiarrhythmic effects
have been offset by their adverse effects, and even increased morbid-
ity and mortality have been observed. Since the initial work done by
Haissaguerre et al.,3 catheter ablation of AF has undergone remark-
able evolution. It has become a more standardized procedure,
with better results and lower complication rates. The key to offering
catheter ablation to an increasing number of patients is to find a
way of combining good clinical results with very low complication
rates.
During the last decade multiple randomized trials have been pub-
lished, comparing catheter ablation treatment to antiarrhythmic
therapy. Most of these studies have been conducted in patients
with paroxysmal AF refractory to one or more antiarrhythmic
drugs. They have shown that ablation is more effective than antiar-
rhythmic therapy in preventing recurrences, with follow-up
periods from 9 to 12 months. Although the evidence is less, we do
have data from randomized trials that also show greater efficacy in
patients with persistent AF refractory to antiarrhythmic therapy.
The SARA study is the first multicentre, randomized study to
compare antiarrhythmic therapy to catheter ablation in patients
with persistent AF of ,1 year. After a 12-month follow-up period,
significantly fewer patients in the ablation group had a recurrence
of AF or atrial flutter lasting .24 h, or need for cardioversion.4
New evidence of the usefulness of ablation has been added with
the publication of trials studying ablation as first-line treatment for
patientswith paroxysmalAF.5,6 In 2012 Cosedis et al. publishedamul-
ticentre, randomized study comparing AF ablation as first-line
therapy to antiarrhythmic therapy in 294 patients with a history of
paroxysmal AF who were followed for 2 years. At the end of follow-
up, the probability of remaining free of AF (85 vs. 71%, P ¼ 0.004) and
symptomatic AF (93 vs. 84%, P ¼ 0.01) and the quality of life, were
significantly higher in the ablation group. However, the cumulative
burden of AF was not significantly different between the two treat-
ment groups (13vs. 19%, P ¼ 0.1).6 In the RAAFT 2 study, a significant
decrease in time to first AF was observed in patients treated with ab-
lation as first-line therapy (54 vs. 72%, P ¼ 0.01).5 Because of these
study results, the indication for catheter ablation as first-line
therapy in patients with paroxysmal AF was raised in the 2012
focused update of the European guidelines for AF treatment to IIa
(level of evidence B)7 from the previous guideline’s IIb (level of evi-
dence B),8 thus supporting the idea that AF ablation has already
crossed the tipping point and become first-line therapy. The guide-
lines state that AF ablation as first-line treatment should be
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considered in selected patients with symptomatic paroxysmal AF,
provided that the procedure is performed at experienced centres
and account is taken of the preferences of patients, who must be ad-
equately informed about the efficacy and safety of the different treat-
ment options available.7
In addition to guidelines, clinical characteristics can help in the se-
lection of patients for whom AF ablation is an option. In cases with
frequent paroxysms of AF, we can offer higher success rates with a
procedure for the ablation of atrial ectopic foci that display frequent
activity, in addition to electrical isolation of the pulmonary veins,
especially if the foci are shown to trigger AF (Figure 1).
The same happens when paroxysmal supraventricular tachycardia
is suspected to cause AF. We also believe the patient must be moti-
vated and willing to undergo repeat ablation procedures, because
data have shown a high recurrence rate in the medium term (4–5
years) after ablation and we know repeat ablation improves efficacy.9
Recent research has been providing encouraging results regarding
the identification of areas involved in AF maintenance in individual
cases, opening the door to more-targeted ablation strategies.10
Furthermore, the development of ablation techniques and the
growingexperienceofprofessionals performing ablationareenabling
us to treat our patients with increasingly safe and more effective pro-
cedures. That is why AF ablation as first-line therapy is already here.
We believe that the future development of the technique will
eventually broaden the indications to even include selected patients
with asymptomatic AF episodes, as happened in the past with the
ablation of other arrhythmic substrates, such as typical atrial flutter
and accessory pathways.
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